Wednesday, December 18, 2024 Permanent trial closure for MAC4 (IBCSG 24-02): A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer and MAC5 (IBCSG 25-02): A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Clinicaltrials.gov Results ReportingMAC4: NCT00066690: Study results have been posted to www.clinicaltrials.gov MAC5: NCT00066703: Study results have been posted to www.clinicaltrials.gov
